Holen Sie sich die Stockscreener-App
13.41
1.82%
0.24
Schlusskurs vom Vortag:
$13.17
Offen:
$13.34
24-Stunden-Volumen:
677.23K
Relative Volume:
2.02
Marktkapitalisierung:
$837.55M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.71M
KGV:
-11.24
EPS:
-1.1935
Netto-Cashflow:
$-54.12M
1W Leistung:
+4.68%
1M Leistung:
+19.41%
6M Leistung:
+104.73%
1J Leistung:
+207.57%
1-Tages-Spanne:
$13.19
$13.78
1-Wochen-Bereich:
$12.95
$17.25
52-Wochen-Spanne:
$3.105
$17.25
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
13.41 | 837.55M | 0 | -69.71M | -54.12M | -1.1935 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Eingeleitet | Jefferies | Buy |
| 2026-01-07 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Scott Coop
Design Therapeutics Set For Multiple Clinical Trial Catalysts In H2 2026 - RTTNews
Oppenheimer Raises Price Target on Design Therapeutics to $21 From $18, Keeps Outperform Rating - marketscreener.com
Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Design Therapeutics (DSGN) price target increased by 12.82% to 14.96 - MSN
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Design Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:DSGN) 2026-04-30 - Seeking Alpha
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Transcript : Design Therapeutics, Inc., Q1 2026 Earnings Call, Apr 28, 2026 - marketscreener.com
Design Therapeutics Q2 2026 slides: multiple data readouts set for 2H By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year High Following Earnings Beat - MarketBeat
Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings - MSN
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Design Therapeutics Q2 2026 slides: multiple data readouts set for 2H - Investing.com Australia
Design Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Design Therapeutics beats Q1 2026 EPS expectations - Investing.com India
Earnings call transcript: Design Therapeutics beats Q1 2026 EPS expectations By Investing.com - Investing.com South Africa
Design Therapeutics 1Q Loss/Shr 29c >DSGN - Moomoo
Design Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Design Therapeutics (NASDAQ: DSGN) Q1 loss, $223M cash and GeneTAC pipeline updates - Stock Titan
Design Therapeutics Reports Q1 2026 Results and Pipeline Progress - TipRanks
Design Therapeutics (NASDAQ:DSGN) Posts Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates - The Manila Times
Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cash runway into 2029 as Design Therapeutics (NASDAQ: DSGN) advances trials - Stock Titan
$222.8M gives Design Therapeutics funding into 2029 as trials advance - Stock Titan
This Biotech Stock Is Down 65%. How a Cancer Trial Was Ruined by Its Own Design. - Barron's
Fathom Therapeutics, Formerly Atommap, Raises $47 Million in Oversubscribed Series A Financing to Translate Physics and AI-Enabled Small Molecule Design into Next-Generation Medicines - PR Newswire
Friedreich's Ataxia Pipeline Enters a Transformative Era with - openPR.com
Friedreich’s Ataxia Pipeline Enters a Transformative Era with 20+ Therapies and Strong Clinical Momentum from Larimar Therapeutics, Minoryx Therapeutics, and Design Therapeutics | DelveInsight - Barchart
Design Therapeutics (DSGN) details 2026 annual meeting, director vote and auditor ratification - Stock Titan
Design Therapeutics (NASDAQ:DSGN) Sets New 52-Week HighStill a Buy? - MarketBeat
Episodic Ataxia Treatment Market Overview, Current Trends, and Key Player Analysis - openPR.com
Design Thera (DSGN) Stock Continuous Quote (Smart Money Flows) 2026-04-15Top Analyst Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month HighShould You Buy? - MarketBeat
Aug Movers: Can Design Therapeutics Inc expand its profit margins2026 Breakouts & Technical Entry and Exit Alerts - baoquankhu1.vn
We Think Design Therapeutics (NASDAQ:DSGN) Can Afford To Drive Business Growth - Yahoo Finance
FOMO Trade: Can Design Therapeutics Inc navigate macro headwinds2026 Price Action Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Astellas Licenses Dyno Therapeutics’ AI-Designed AAV Capsid, Advancing Gene Delivery for Muscle Disorders - BioPharm International
Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings (XLV:NYSEARCA) - Seeking Alpha
US Market Wrap: What is the long term forecast for Design Therapeutics Inc stock2026 Volume Leaders & Proven Capital Preservation Methods - baoquankhu1.vn
Is Design Thera (DSGN) Stock at a Peak | Price at $12.50, Down 1.34%Growth Picks - Cổng thông tin điện tử Tỉnh Sơn La
DSGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design - Business Wire
PTCT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Design Therapeutics (NASDAQ:DSGN) Trading Up 6.8%Still a Buy? - MarketBeat
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):